GlobeNewswire

Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

Share
  • Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment
  • New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs
  • More sensitive than traditional Pap cytology, this test allows clinicians to determine which HPV-positive women require further diagnostic procedures to prevent disease progression

Basel, 16 September 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval for the expanded use of CINtec® PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). Additional information from this test supports clinical decisions about which women will benefit most from immediate follow-up. Laboratories can now use CINtec PLUS Cytology to triage positive results from the cobas® HPV Test run on the fully integrated, automated and high-throughput cobas® 6800/8800 Systems.

High-risk HPV is the principal cause of cervical cancer, which is one of the most common cancers in women globally. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

“With our portfolio of cervical cancer tests and automated testing platforms, we are committed to providing clinicians and laboratories with the best tools possible to protect women’s health,” said Thomas Schinecker, CEO Roche Diagnostics. “This expanded indication for CINtec PLUS Cytology gives laboratories the flexibility to triage cobas HPV test results on their choice of cobas® Systems and deliver accuracy needed to reliably detect HPV infections that are starting to cause cellular changes that could lead to cancer. The biomarker information helps to clarify a woman’s risk of disease, reduce the potential for over- or under-treatment, and is a major step forward in individualising a woman’s care.”

HPV DNA screening identifies women at risk for cervical cancer by detecting the presence of high-risk HPV DNA in cervical samples. While most HPV infections resolve on their own, some women who test positive for the virus, or whose co-testing results are discrepant (HPV positive/Pap cytology negative), may have or may develop pre-cancerous cervical lesions. These lesions could progress to cervical cancer if left untreated.

About human papillomavirus and cervical cancer

Persistent infection with high-risk human papillomavirus (HPV) is the principal cause of cervical cancer in women, with HPV implicated in greater than 99 percent of cervical cancers worldwide.1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; expanding access helps reach more women in underserved communities where the disease burden is highest.2,3 It can take 10 to 15 years or longer for cervical cancer to develop, so knowing a woman’s individual risk and finding disease early, before cancer develops, is an important prevention strategy.

About 13,800 new cases of invasive cervical cancer will be diagnosed in the U.S. in 2020, according to the American Cancer Society, and about 4,290 women will die from the disease this year. Globally, the World Health Organization estimates there are more than 570,000 new cases of cervical cancer annually, and 311,000 deaths.4 Learn more about the Roche Cervical Cancer Global Access Program.

About CINtec PLUS Cytology
The CINtec PLUS Cytology test detects the simultaneous presence within a single cell of the two biomarkers -- p16 and Ki-67. This abnormality is associated with HPV infections that are transforming and can, if left untreated, progress to pre-cancer or cancer. A positive result of these two biomarkers in a single cell signals that a woman is more significantly at risk for disease. The ability of CINtec PLUS Cytology to distinguish those women who are at higher risk for cervical disease provides labs, physicians and women, in conjunction with the clinician’s assessment of patient screening history, other risk factors, and professional guidelines information, to guide patient management. Women with negative dual stain results are at significantly lower risk for cervical disease and their bodies can be given more time to clear HPV infection on their own. This could reduce the number and frequency of follow-up visits, saving some patients worry and time.

The CINtec PLUS Cytology test, which runs on the BenchMark ULTRA IHC/ISH system, is performed using the same sample that is used for HPV or liquid-based Pap cytology tests. This eliminates the need for additional or repeat sample collection or time spent waiting to find out if an infection is clearing.

For U.S. approval, the FDA considered data from the Roche-sponsored registrational IMPACT (IMproving Primary screening And Colposcopy Triage) trial, which enrolled approximately 35,000 women in the U.S. to clinically validate CINtec PLUS Cytology as a triage test in various screening scenarios. This latest expanded use approval gives laboratories access to the complete Roche Cervical Cancer Portfolio offering in the U.S., which includes the cobas HPV Test, CINtec PLUS Cytology and CINtec Histology. Depending on their workflow needs, labs now have the choice to fully automate their highest volume assays and utilise biomarker technology to offer more advanced, next-generation cytology solutions. Publication of the full IMPACT study findings is pending.

Prior to FDA approvals for its use for the triage of women who are HPV positive using the cobas HPV Test on the cobas® 4800 or cobas 6800/8800 Systems, the CINtec PLUS Cytology CE-IVD test had been used as a triage test for HPV-positive results and mildly abnormal Pap cytology results in Europe, Asia, South America, Canada and Australia.

About the Roche Cervical Cancer Portfolio
The Roche Cervical Cancer Portfolio enables healthcare professionals to screen, triage and diagnose women, based on the confidence and clarity of results across a continuum of patient care. The unique combination of molecular, cellular cytology and tissue-based tests provides healthcare professionals powerful information to make patient care decisions and minimise unnecessary treatment. Along with cobas HPV for screening, and CINtec PLUS Cytology, CINtec Histology is used as an aid to confirm the presence of cervical disease in women who have had a tissue biopsy. CINtec Histology is the only FDA-cleared test that uses the p16 biomarker for a more conclusive diagnosis to provide distinctive visual confirmation of precancerous cervical lesions that may be missed by hematoxylin and eosin (H&E) interpretation alone. Like CINtec PLUS Cytology, CINtec Histology is also fully automated on the BenchMark IHC/ISH instruments.

About the BenchMark ULTRA IHC/ISH system
The BenchMark ULTRA system is a fully automated immunohistochemistry and in situ hybridization slide staining system, offering multiple features designed to provide diagnostic confidence to histopathology laboratories worldwide. With 30 independent slide drawers, the system gives histotechnologists continuous random access and supports single-piece workflow, which numerous studies have shown improves laboratory operational efficiency.

About cobas Systems
cobas HPV tests run on cobas Systems and are indicated for use for routine cervical cancer screening to assess the risk in women for cervical precancer and cancer as per professional medical guidelines, including primary screening, triage of ASC-US cytology and co-testing (or adjunctive screen) with cytology. These real-time PCR systems serve the areas of infectious disease, donor screening, sexual health, transplant, respiratory and antimicrobial stewardship.  They are also part of the Molecular Work Area—a fully integrated laboratory workflow solution that empowers labs to significantly elevate their levels of efficiency, flexibility and scalability.  When every moment matters, the fully automated cobas 6800/8800 Systems offer the fastest time to results with the highest throughput and the longest walk-away time available among automated molecular platforms. With proven performance, absolute automation and unmatched flexibility delivering unparalleled throughput 24/7—cobas 6800/8800 Systems are designed to ensure a lab’s long-term sustainability and success … now, more than ever. Learn more now: www.cobas68008800.com.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

BENCHMARK, CINTEC and COBAS are trademarks of Roche. All other trademarks are the property of their respective owners.

References
[1] Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12-19.
[2] Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016; 2:16086.
[3] Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 8:I1-31.
[4] World Health Organization, www.who.int/health-topics/cervical-cancer#tab=tab_2


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17

Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10

Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74

Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Touax: Success of the partial buyback of the Undated Deeply Subordinated Bond27.11.2020 17:45:00 CETPress release

PRESS RELEASE Paris, November 27, 2020 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Success of the partial buyback of the Undated Deeply Subordinated Bond Touax SCA announces today that it has bought back and canceled part of the Undated Deeply Subordinated Bond issued in August 2013, November 2013 and May 2014, for a nominal amount of 24.2 million euros. The outstanding amount of the bonds stands at 26.6 million euros. This operation will enable to optimize the capital structure of the Group and to lower the related costs. Fabrice and Raphaël Walewski, managing partners of Touax Group commented: “The strategic refocusing initiated since 2018 around the long-term rental business of environmentally-friendly transport equipment has allowed a return to growth and profit over the first half of 2020. The capital increase of Touax Rail for 81.9 million euros achieved at the end of September 2020 significantly strengthened the capital of the Rail division and t

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS27.11.2020 16:20:00 CETPress release

Anbudsförfarande kommuner och regioner, 2020-12-01BondsFixed rate notes issued in SEK by Municipalities or Regions with maturity in: 2025 The following issuers are accepted for delivery: Göteborgs Stad Jönköpings Kommun Malmö Stad Nacka Kommun Region Skåne Stockholms Stad Region Stockholm Vellinge Kommun Västerås Stad Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after: 2020-11-20BidsBids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se Bid date2020-12-01Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 750 +/- 750 millionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million. No bid may contain Bonds exceeding SEK 750 millio

CONDITIONS FOR PURCHASES OF CORPORATE BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-02BondsBonds issued in SEK by Swedish non-financial undertakings. The following bonds are eligible for delivery: VASAKRONAN AB: XS1941844174, 2022-02-11 VASAKRONAN AB: XS2051470552, 2024-09-11 HEMSO FASTIGHETS AB: XS1876163103, 2022-03-07 HEMSO FASTIGHETS AB: XS1938445530, 2021-10-22 VOLVO TREASURY AB: XS2153414292, 2022-12-08 VOLVO TREASURY AB: XS2018763461, 2021-06-28 HUSQVARNA AB: SE0009664543, 2022-03-01 HUSQVARNA AB: SE0010869669, 2023-02-14 AB INDUSTRIVARDEN: SE0011869668, 2022-02-28 AB INDUSTRIVARDEN: SE0012676724, 2023-02-20 Delivery of a Bond may not occur if the Counterparty has purchased the Bond from the issuer more recently than one month prior to the date of announcement of the Special terms, that is, the purchase may not have taken place after: 2020-11-02Bid date2020-12-02Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)XS1941844174: 30 mln SEK +/-30 mln SEK XS2051470552: 30 mln SEK +/-30 mln SEK XS18761

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-03BondsSTADSHYPOTEK AB: 1590, SE0012676690, 2025-09-03 SWEDBANK HYPOTEK AB: 194, SE0012142206, 2024-09-18 NORDEA HYPOTEK AB: 5535, SE0013358413, 2025-09-17 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 518, SE0011309244, 2025-09-17 DANSKE HYPOTEK AB: 2512, SE0013877214, 2025-12-17 SWEDISH COVERED BOND: 146, SE0013381571, 2025-06-11 Bid date2020-12-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1590: 1200 mln SEK +/-600 mln SEK 194: 1000 mln SEK +/-500 mln SEK 5535: 1000 mln SEK +/-500 mln SEK 580: 800 mln SEK +/-400 mln SEK 518: 600 mln SEK +/-300 mln SEK 2512: 300 mln SEK +/-150 mln SEK 146: 600 mln SEK +/-300 mln SEK Maximum 5500 mln in totalHighest permitted bid volume (corresponding nominal amount)1590: 1200 mln SEK per bid 194: 1000 mln SEK per bid 5535: 1000 mln SEK per bid 580: 800 mln SEK per bid 518: 600 mln SEK per bid 2512: 300 mln SEK per bid 146: 600 mln SEK per bid Lo

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS27.11.2020 16:20:00 CETPress release

Bid procedure, 2020-12-04BondsSWEDEN I/L BOND: 3108, SE0004211084, 2022-06-01 SWEDEN I/L BOND: 3109, SE0005703550, 2025-06-01 Bid date2020-12-04Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)3108: 500 mln SEK +/-250 mln SEK 3109: 500 mln SEK +/-250 mln SEK Maximum 1000 mln in totalHighest permitted bid volume (corresponding nominal amount)3108: 500 mln SEK per bid 3109: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNo later than 10.10 (CET/CEST) on the Bid dateDelivery and payment date2020-12-08Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2020-11-27 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete term

Greenfield cement project in Ethiopia is effective27.11.2020 15:45:28 CETPress release

Company Announcement No. 21 -2020, 3 November 2020 The previously announced signed contract for engineering, procurement and supervision on a cement plant in Ethiopia (Company Announcement No. 1-2019 on 24 January 2019) with Abay Industrial Development Share Company, is now effective. Located near the city of Dejen in Ethiopia, the new greenfield plant will play an important role for the development of local infrastructure. Once fully operational the plant will have a capacity of 5,000 tonnes per day and creating more than 300 new jobs in the area. The contract is valued at around EUR 100 million. The order includes design and engineering, full equipment supply, automation systems, installation and commissioning as well as training and extended supervision. Key deliveries are expected to commence towards the end of 2021. The majority of revenue from this project is expected in the subsequent years. “We are happy to see the contract now in effect,” said Carsten Riisberg Lund, President,